How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme
Since the discovery of phosphodiesterase-5 (PDE5) enzyme overexpression in the central
nervous system (CNS) malignancies, investigations have explored the potential capacity of …
nervous system (CNS) malignancies, investigations have explored the potential capacity of …
[HTML][HTML] Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome
V Cesarini, M Martini, LR Vitiani, GL Gravina… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Expression of type 5 phosphodiesterase (PDE5), a cGMP-specific hydrolytic enzyme, is
frequently altered in human cancer, but its specific role in tumorigenesis remains …
frequently altered in human cancer, but its specific role in tumorigenesis remains …
Recent advances of Phosphodiesterase 4B in cancer
Y Miao, L Peng, Z Chen, Y Hu, L Tao… - Expert Opinion on …, 2023 - Taylor & Francis
ABSTRACT Introduction Phosphodiesterase 4B (PDE4B) is a crucial enzyme in the
phosphodiesterases (PDEs), acting as a regulator of cyclic adenosine monophosphate …
phosphodiesterases (PDEs), acting as a regulator of cyclic adenosine monophosphate …
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression
P Goldhoff, NM Warrington, DD Limbrick Jr… - Clinical Cancer …, 2008 - AACR
Purpose: As favorable outcomes from malignant brain tumors remain limited by poor survival
and treatment-related toxicity, novel approaches to cure are essential. Previously, we …
and treatment-related toxicity, novel approaches to cure are essential. Previously, we …
[HTML][HTML] Phosphodiesterase type 5 and cancers: Progress and challenges
Cancers are an extraordinarily heterogeneous collection of diseases with distinct genetic
profiles and biological features that directly influence response patterns to various treatment …
profiles and biological features that directly influence response patterns to various treatment …
Phosphodiesterase type 5 as a candidate therapeutic target in cancers
The global burden of cancer is largely increasing because of population aging and growth
alongside an adoption of cancer-causing lifestyle choices. The majority of cancers can be …
alongside an adoption of cancer-causing lifestyle choices. The majority of cancers can be …
Cyclic nucleotide phosphodiesterase‐1C (PDE1C) drives cell proliferation, migration and invasion in glioblastoma multiforme cells in vitro
FB Rowther, W Wei, TP Dawson… - Molecular …, 2016 - Wiley Online Library
Cyclic nucleotides (cAMP & cGMP) are critical intracellular second messengers involved in
the transduction of a diverse array of stimuli and their catabolism is mediated by …
the transduction of a diverse array of stimuli and their catabolism is mediated by …
Targeting cancer with phosphodiesterase inhibitors
R Savai, SS Pullamsetti, GA Banat… - Expert opinion on …, 2010 - Taylor & Francis
Importance of the field: For many cancers, there has been a shift from management with
traditional, nonspecific cytotoxic chemotherapies to treatment with molecule-specific …
traditional, nonspecific cytotoxic chemotherapies to treatment with molecule-specific …
Treating brain tumors with PDE4 inhibitors
Speculation regarding dysregulation of cAMP metabolism in oncogenesis has existed since
the discovery of cAMP more than 50years ago. Recent data confirm the relevance of …
the discovery of cAMP more than 50years ago. Recent data confirm the relevance of …
Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells
L Booth, JL Roberts, N Cruickshanks, A Conley… - Molecular …, 2014 - ASPET
The present studies determined whether clinically relevant phosphodiesterase 5 (PDE5)
inhibitors interacted with clinically relevant chemotherapies to kill gastrointestinal …
inhibitors interacted with clinically relevant chemotherapies to kill gastrointestinal …